Activyl Tick Plus

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

indoxacarb, permethrin

Available from:

Intervet International BV

ATC code:

QP53AC54

INN (International Name):

indoxacarb, permethrin

Therapeutic group:

Psi

Therapeutic area:

permethrin, kombinacije, Ectoparasiticides za lokalno uporabo, vključno. insekticidi

Therapeutic indications:

Zdravljenje infestacij bolh (Ctenocephalides felis); izdelek ima trajno insekticidno učinkovitost do 4 tedne proti Ctenocephalides felis. Zdravilo ima trajno akaricidno učinkovitost do 5 tednov proti Ixodes ricinusu in do 3 tedne proti Rhipicephalus sanguineus. Ena obdelava zagotavlja repelentno (anti-hranjenje) aktivnost proti peskom (Phlebotomus perniciosus) do 3 tedne.

Product summary:

Revision: 9

Authorization status:

Umaknjeno

Authorization date:

2012-01-09

Patient Information leaflet

                                19
B. NAVODILO ZA UPORABO
Zdravilo nima veā dovoljenja za promet
20
NAVODILO ZA UPORABO:
Activyl Tick Plus kožni nanos, raztopina za pse
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ , ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
Nizozemska
Proizvajalec, odgovoren za sproščanje serij:
Intervet Productions SA
Rue de Lyons
27460 Igoville
Francija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Activyl
Tick Plus 75 mg + 240 mg, kožni nanos, raztopina za zelo majhne pse
Activyl
Tick Plus 150 mg + 480 mg, kožni nanos, raztopina za majhne pse
Activyl Tick Plus 300 mg + 960 mg, kožni nanos, raztopina za srednje
velike pse
Activyl Tick Plus 600 mg + 1920 mg, kožni nanos, raztopina za velike
pse
Activyl Tick Plus 900 mg + 2880 mg, kožni nanos, raztopina za zelo
velike pse
Indoksakarb + permetrin
3.
NAVEDBA UČINKOVIN(E) IN DRUG(E)IH SESTAVIN
UČINKOVINA:
1 ml vsebuje indoksakarb 150 mg in permetrin 480 mg
Ena merilna kapalka vsebuje:
VOLUMEN
(ML)
INDOKSAKARB
(MG)
PERMETRIN
(MG)
Za zelo majhne pse (1,2 – 5 kg)
0,5
75
240
Za majhne pse (5.1 – 10 kg)
1
150
480
Za srednje velike pse (10,1 – 20 kg)
2
300
960
Za velike pse (20,1 – 40 kg)
4
600
1920
Za zelo velike pse (40,1 – 60 kg)
6
900
2880
Bistra brezbarvna do rumena ali rjava raztopina
4.
INDIKACIJA(E)
Zdravljenje infestacije z bolhami (
_Ctenocephalides felis_
); zdravilo deluje insekticidno do 4 tedne na
_Ctenocephalides felis. _
Zdravilo deluje akaricidno do 5 tednov na
_Ixodes ricinus_
in do 3 tedne na
_Rhipicephalus sanguineus_
.
Če so klopi teh vrst prisotni, ko nanašate zdravilo, morda vsi ne
bodo uničeni v enem tednu.
Razvojne stopnje bolh v neposredni okolici psa se po stiku z
zdravljenimi psi uničijo.
Zdravilo nima veā dovoljenja za promet
21
Eno zdravlejnje zagotavlja repelentno delovanje (prenehanje hranjenja)
proti peščenim muham
(
_Phlebotomus perniciosus) _
za do 3 tedne.
5.
KONTR
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
Zdravilo nima veā dovoljenja za promet
2
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Activyl Tick Plus 75 mg + 240 mg kožni nanos, raztopina za zelo
majhne pse
Activyl Tick Plus 150 mg + 480 mg kožni nanos, raztopina za majhne
pse
Activyl Tick Plus 300 mg + 960 mg kožni nanos, raztopina za srednje
velike pse
Activyl Tick Plus 600 mg + 1920 mg kožni nanos, raztopina za velike
pse
Activyl Tick Plus 900 mg + 2880 mg kožni nanos, raztopina za zelo
velike pse
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
UČINKOVINA:
En ml vsebuje 150 mg indoksakarba in 480 mg permetrina.
En enkratni odmerek v kapalki vsebuje:
ENKRATNI ODMEREK
(ML)
INDOKSAKARB
(MG)
PERMETRIN
(MG)
Zelo majhni psi (1,2 - 5 kg)
0,5
75
240
Majhni psi (5,1 - 10 kg)
1
150
480
Srednje veliki psi (10,1 - 20 kg)
2
300
960
Veliki psi (20,1 - 40 kg)
4
600
1920
Zelo veliki psi (40,1 - 60 kg)
6
900
2880
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Kožni nanos, raztopina.
Bistra brezbarvna do rumena ali rjava raztopina.
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Psi.
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Zdravljenje infestacije z bolhami (
_Ctenocephalides felis_
); zdravilo deluje insekticidno do 4 tedne na
_Ctenocephalides felis. _
Zdravilo deluje akaricidno do 5 tednov na
_Ixodes ricinus_
in do 3 tedne na
_Rhipicephalus sanguineus_
.
Če so klopi teh vrst prisotni, ko nanašate zdravilo, morda vsi ne
bodo uničeni v prvih 48 urah ampak v
enem tednu.
Razvojne stopnje bolh v neposredni okolici psa se po stiku z
zdravljenimi psi uničijo.
Eno zdravljenje zagotavlja repelentno delovanje (preprečevanje
hranjenja) proti peščenim muham
(
_Phlebotomus perniciosus) _
za do 3 tedne.
4.3
KONTRAINDIKACIJE
Ne uporabljajte za mačke zaradi možnosti pojava neželenih učinkov
in celo smrti (glejte poglavje 4.5
Posebni previdnostni ukrepi).
Ne uporabljajte v primerih znane preobčutljivosti na učinkovine ali
na katero od pomožnih snovi.
Zdravilo ni
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-10-2022
Public Assessment Report Public Assessment Report Bulgarian 04-10-2022
Patient Information leaflet Patient Information leaflet Spanish 04-10-2022
Public Assessment Report Public Assessment Report Spanish 04-10-2022
Patient Information leaflet Patient Information leaflet Czech 04-10-2022
Public Assessment Report Public Assessment Report Czech 04-10-2022
Patient Information leaflet Patient Information leaflet Danish 04-10-2022
Public Assessment Report Public Assessment Report Danish 04-10-2022
Patient Information leaflet Patient Information leaflet German 04-10-2022
Public Assessment Report Public Assessment Report German 04-10-2022
Patient Information leaflet Patient Information leaflet Estonian 04-10-2022
Public Assessment Report Public Assessment Report Estonian 04-10-2022
Patient Information leaflet Patient Information leaflet Greek 04-10-2022
Public Assessment Report Public Assessment Report Greek 04-10-2022
Patient Information leaflet Patient Information leaflet English 04-10-2022
Public Assessment Report Public Assessment Report English 04-10-2022
Patient Information leaflet Patient Information leaflet French 04-10-2022
Public Assessment Report Public Assessment Report French 04-10-2022
Patient Information leaflet Patient Information leaflet Italian 04-10-2022
Public Assessment Report Public Assessment Report Italian 04-10-2022
Patient Information leaflet Patient Information leaflet Latvian 04-10-2022
Public Assessment Report Public Assessment Report Latvian 04-10-2022
Patient Information leaflet Patient Information leaflet Lithuanian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-10-2022
Public Assessment Report Public Assessment Report Lithuanian 04-10-2022
Patient Information leaflet Patient Information leaflet Hungarian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 04-10-2022
Public Assessment Report Public Assessment Report Hungarian 04-10-2022
Patient Information leaflet Patient Information leaflet Maltese 04-10-2022
Public Assessment Report Public Assessment Report Maltese 04-10-2022
Patient Information leaflet Patient Information leaflet Dutch 04-10-2022
Public Assessment Report Public Assessment Report Dutch 04-10-2022
Patient Information leaflet Patient Information leaflet Polish 04-10-2022
Public Assessment Report Public Assessment Report Polish 04-10-2022
Patient Information leaflet Patient Information leaflet Portuguese 04-10-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 04-10-2022
Public Assessment Report Public Assessment Report Portuguese 04-10-2022
Patient Information leaflet Patient Information leaflet Romanian 04-10-2022
Public Assessment Report Public Assessment Report Romanian 04-10-2022
Patient Information leaflet Patient Information leaflet Slovak 04-10-2022
Public Assessment Report Public Assessment Report Slovak 04-10-2022
Patient Information leaflet Patient Information leaflet Finnish 04-10-2022
Public Assessment Report Public Assessment Report Finnish 04-10-2022
Patient Information leaflet Patient Information leaflet Swedish 04-10-2022
Public Assessment Report Public Assessment Report Swedish 04-10-2022
Patient Information leaflet Patient Information leaflet Norwegian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 04-10-2022
Patient Information leaflet Patient Information leaflet Icelandic 04-10-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 04-10-2022
Patient Information leaflet Patient Information leaflet Croatian 04-10-2022
Public Assessment Report Public Assessment Report Croatian 04-10-2022

Search alerts related to this product